Reducing bladder tumor recurrence with narrow band imaging

Researchers from the University of Birmingham in the United Kingdom have found that utilization of narrow band imaging can substantially reduce the risk of recurrence from bladder cancer, according to results of a new study published in European Urology.

With approximately 430,000 new cases diagnosed each year, bladder cancer is the ninth most common cancer in the world, according to statistics from the World Cancer Research Fund.

The traditional treatment method is through resection, but tumor recurrence following surgery is common due to uncertainty as to whether cancerous tissues have been completely removed. Emerging treatments, including surgery guided by narrow band imaging, could help fix the problem and reduce tumor recurrence.

University researchers, in coordination with the clinical research office of the Endourological Society, compared two groups of bladder cancer patients who had to undergo bladder tumor resection surgery: low-risk patients who underwent image-guided surgery using narrow band imaging, and patient who underwent conventional bladder tumor surgery.

Their results showed that only 5.6 percent of patients in the narrow band imaging surgery group had tumor recurrence after a year following surgery, while 27 percent of those who had conventional resection had recurrence of bladder tumors.

"Narrow band imaging makes it easier to identify bladder tumors,” said researcher Richard Bryan in a university press release. “It can detect small bladder tumors that might otherwise by overlooked by more conventional 'white light' cystoscopy."

 

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.